ClinicalTrials.gov
ClinicalTrials.gov Menu

British Randomised Controlled Trial of Atrioventricular (AV) and Interventricular (VV) Optimisation (BRAVO) (BRAVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01258829
Recruitment Status : Completed
First Posted : December 13, 2010
Last Update Posted : June 30, 2015
Sponsor:
Collaborator:
University of Aberdeen
Information provided by (Responsible Party):
Imperial College London

Brief Summary:

Many patients who have cardiac resynchronisation therapy (a type of pacemaker) implanted for heart failure do not have the settings of their device optimised. The most widely available method for optimisation uses flow measured using cardiac ultrasound (echocardiography) to determine the optimal settings. However, this is not frequently performed because it is time consuming and requires two skilled operators. In this study the investigators will test a new non-invasive method for optimisation, which utilises pressure measurements (non-invasive blood pressure measured from the finger).

Is optimising AV and VV delay using non-invasive haemodynamics at least equivalent, in terms of exercise capacity, to conventional echo optimisation.


Condition or disease Intervention/treatment Phase
Heart Failure Other: Non-invasive haemodynamic optimisation Other: ECHO optimisation Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 403 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: British Randomised Controlled Trial of AV and VV Optimisation (BRAVO): Randomised Clinical Trial of the Effects of Non-invasive Haemodynamic Optimisation of Cardiac Resynchronisation Devices on Exercise Capacity
Study Start Date : December 2010
Actual Primary Completion Date : January 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Non-invasive haemodynamic optimisation
Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
Other: Non-invasive haemodynamic optimisation
Comparing the method of non-invasive haemodynamic
Active Comparator: ECHO optimisation
Optimization of AV/VV delay using the guideline recommendations
Other: ECHO optimisation
Standard ECHO optimisation method



Primary Outcome Measures :
  1. Is optimising AV and VV delay using non-invasive haemodynamics at least equivalent, in terms of exercise capacity, to conventional echo optimisation [ Time Frame: 6 months following the last follow-up of the last patient ]

Secondary Outcome Measures :
  1. To determine whether pressure optimisation is at least equivalent to echo optimisation of flow: in terms resulting size of the heart in terms of quality of life scores in terms of blood marker of heart failure severity [ Time Frame: 6 months following the last follow-up of the last patient ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic heart failure due to systolic dysfunction
  • Biventricular pacemaker implanted
  • Give written informed consent

Exclusion Criteria:

  • Lung disease or any condition that would preclude them from walking on a treadmill

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01258829


Locations
United Kingdom
ICCH, Imperial College London
London, United Kingdom
Sponsors and Collaborators
Imperial College London
University of Aberdeen
Investigators
Principal Investigator: Dr Darrel Francis Imperial College London

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01258829     History of Changes
Other Study ID Numbers: 10/H0803/86
First Posted: December 13, 2010    Key Record Dates
Last Update Posted: June 30, 2015
Last Verified: May 2014

Keywords provided by Imperial College London:
Heart Failure Cardiac Resynchronisation Therapy

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases